Introduction

Allograft reconstruction is one of the functional reconstructive options, as a biologic reconstructive alternative to the bone defect in limb salvage surgery. However, allograft transplantation after malignant bone tumor and aggressive benign bone tumor have shown a high rate of complications. Mankin et al reported the complications of allograft in 870 massive frozen cadaveric allografts over a long term. During the first 3 years complications including fracture (19%), nonunion (17%) and infection (11%) before achieving stability with their grafts. Many other authors reported similar results concerning complication after allograft reconstruction. The most common causes of graft failure are limited incorporation of the allograft into host tissue, infections, fractures, or unopposed resorption. Early vascular invasion is a critical factor in bone allograft incorporation and consequent success of the surgery. Bone formation is correlated with better vascular invasion and remodeling of the graft. However, it has been proven that only slow and incomplete bone integration is possible by using frozen allografts in the treatment of bone defects. Therefore, accelerating and increasing the revascularization may be critical to allow bone healing and integration. In this context, vascularized autografts retain their biologic and mechanical properties, heal by primary union, and can result in hypertrophy in response to load. Moreover, there is hypothesis that the use of autologous bone marrow mononuclear cell has a role in the re-building of large segmental defects.

The purpose of this study was to evaluate the complications of reconstruction after a bone tumor resection, and reviewed literatures to overcome such complications.

Materials and Methods: We retrospectively reviewed clinical records and radiographs of fifteen patients in whom reconstruction with allograft after bone tumor resection.

Results: Eight patients were men and seven were women with a mean age of 27.1 years (1-56 years) and a mean follow-up period of 89.5 months (33-165 months). All postoperative complications related to the allograft were recorded. Twenty patients (80.0%) obtained a radiologic bony union at a mean of 8.35 months (4-12 months). The mean Musculoskeletal Tumor Society score was 73.5% (46.6-93.0%). Nine patients (60.0%) experienced one event and 3 (20.0%) patients experienced multiple events during the follow-up period. Recorded events were infection (3), fracture (2), nonunion (2), limb length discrepancy (2) and varus deformity (2). The mean event free survival period was 60.8 months (6-144 months). The mean allograft survival period was 80.2 months and the 5 year survival rate of the allografts was 83.0%.

Conclusion: In order to overcome complications, the combination of an allograft and vascularized fibular graft is highly recommended. In the near future, the tissue engineering technique, the application of the stem cell and PRP, could reduce the complication of allograft such as resorption and nonunion.

Key words: bone tumor, allograft transplantation, complication
Materials and Methods

We retrospectively reviewed the records of consecutive patients who underwent allograft reconstruction between 1990 and 2008. Inclusion criteria included (1) implantation of an allograft for treatment of aggressive benign bone tumor and malignant bone tumor; (2) absence of prior surgical treatments for the bone tumor; (3) complete clinical, radiographic, and pathologic records; and (4) minimum follow-up period of 2 years since allograft reconstruction. We calculated the postoperative follow-up period from the date of the primary allograft surgery to the most recent patient encounter or death.

We observed twenty-six patients who had allograft reconstruction performed by one surgeon. We excluded eleven patients who had less than two years of follow-up period, and nine of eleven who died within two years of the initial allograft implantation. Two of eleven patients were excluded because of insufficient clinical information due to follow-up loss. The remaining fifteen patients were the subjects of this study.

Eight patients were men and seven were women with a mean age of 27.1 (range, 1–56 years) at the time of surgery and a minimum follow-up period of 33 months (mean, 89.5 months; range 33–166 months). The diagnoses were osteosarcoma in nine patients, chondrosarcoma in three patients, giant cell tumor in two patients and metastatic bone tumor in one patient. The types of reconstruction were the intercalary reconstructions in five patients, allograft–prosthesis composites in four patients, osteoarticular reconstructions in three patients, and arthrodesis in two patients. Ten patients received chemotherapy, and five patients with chondrosarcoma or giant cell tumor did not receive chemotherapy (Table 1).

The operative procedures conformed to principles of the management of malignant and aggressive bone tumors. No surgical margins of resection were positive according to the operation records and the pathologic reports. We used fresh–frozen cadaveric allografts for reconstruction. Reconstruction of the ligaments, tendons, and joint capsule were handled as meticulously and carefully as possible. Immobilization was performed in all cases with either casts or splints for a minimum of 6 weeks, on a case–by–case basis.

All postoperative complications related to the allograft transplantation were recorded. We also focused on the treatment that was given for each complication (Table 1). The events consisted of surgical addition of allograft for structural support, revision of any part of the allograft, and removal of the allograft. We recorded specific events as following way. Nonunion was defined as no evidence of radiographic bridging of the approximated ends between allograft.

Table 1. Patients’ Characteristics

| No | Age | Sex | Location | Diagnosis | Type of reconstruction | Union (months) | Functional score (%) | Oncologic result | Follow-up (months) | Event number | Event-free survival (months) | Allograft survival (months) |
|----|-----|-----|----------|-----------|------------------------|---------------|---------------------|------------------|-------------------|-------------|----------------------------|-----------------------------|
| 1  | 12  | M   | PT       | Osa       | Arthrodesis            | 12            | 60                  | NED              | 127               | 2           | 69                        | 74                          |
| 2  | 24  | M   | Pelvis   | Chondrosa | Arthrodesis            | 4             | 50                  | CDF              | 113               | 1           | 101                      | 113                         |
| 3  | 1   | M   | PT       | Osa       | Intercalary            | 8             | 76                  | CDF              | 165               | 1           | 21                       | 165                         |
| 4  | 6   | F   | DF       | Osa       | Intercalary            | 9             | 76                  | CDF              | 58                | 1           | 37                       | 58                          |
| 5  | 37  | F   | ST       | Osa       | Intercalary            | 83            | 76                  | CDF              | 76                | 1           | 6                        | 76                          |
| 6  | 56  | F   | PF       | MBT       | APC                    | 9             | 60                  | CDF              | 166               | 1           | 98                       | 98                          |
| 7  | 13  | M   | PH       | Osa       | Osteoarticular         | 46.6          | 47                  | CDF              | 9                 | 2           | 29                       |                             |
| 8  | 44  | M   | PT       | Chondrosa | Intercalary            | 12            | 77                  | CDF              | 40                | 2           | 21                       | 40                          |
| 9  | 14  | F   | DF       | Osa       | APC                    | 5             | 83                  | CDF              | 128               | 0           | 128                      | 128                         |
| 10 | 11  | F   | PT       | Osa       | Intercalary            | 11            | 93                  | CDF              | 110               | 0           | 110                      | 110                         |
| 11 | 31  | F   | PH       | Osa       | Osteoarticular         | 12            | 90                  | CDF              | 144               | 0           | 144                      | 144                         |
| 12 | 53  | F   | Patella  | Osa       | Osteoarticular         | 83            | 33                  | CDF              | 33                | 0           | 33                       |                             |
| 13 | 22  | M   | DF       | GCT       | Intercalary            | 4             | 83                  | CDF              | 46                | 0           | 46                       | 46                          |
| 14 | 46  | M   | DF       | GCT       | APC                    | 9             | 83                  | CDF              | 38                | 0           | 38                       | 38                          |
| 15 | 37  | M   | Pelvis   | Chondrosa | APC                    | 5             | 60                  | CDF              | 52                | 0           | 52                       | 52                          |

Average 27.1 8.3 73.6 89.5 0.8 60.8 80.2

PT, proximal tibia; Osa, osteosarcoma; NED, no evidence of disease; Chondrosa, chondrosarcoma; CDF, continuous disease free; DF, distal femur; ST, shaft tibia; PF, proximal femur; MBT, metastatic bone tumor; APC, allograft–prosthesis composite; PH, proximal humerus; GCT, giant cell tumor.
and host bone on two consecutive radiographs taken, at least two months apart in a minimum of 6 months from the index procedure. Limb leg discrepancy was observed in an immature skeletal patient after allograft transplantation. Implant/prosthesis infection involved various extents, from simple wound problems such as marginal necrosis to deep infections due to allograft. The evaluation criteria of Musculoskeletal Tumor Society 1993 was used for functional evaluation and radiologic bony union was evaluated at the last follow-up.

Event-free survival, allograft survival and patient survival were assessed with Kaplan-Meier survival analysis. The end point for event-free survival was the time of occurrence of first event, and for patients who did not experience an event, the date of the last follow-up. The end point for allograft survival was the date of allograft removal or amputation or the date of last follow up for patients who retained their allograft. The end point for patient survival was the date of death or last date the patient was known to be alive.

Results

Twelve of fifteen patients (80.0%) obtained a radiologic bony union at mean of 8.35 months (range, 4–12 months). Two patients with nonunion were treated by plate fixation and autogenous iliac bone graft. Bony union was not observed in one patient (case 12) because reconstruction in this patient was performed mostly between soft tissues (Table 2).

Nine of fifteen patients (60.0%) experienced an event during the follow-up period, and three patients (case 1, 7, 8) experienced multiple events (Fig. 1). Three patients (20.0%) had infections, and the infected allograft was removed in two patient (case 6, 7). Two patients (13.3%) had allograft fractures, and one patient (case 1) was treated by multiple plating and bone graft, and the other (case 8) was treated by long leg cast. Two patients (13.3%) had varus deformities (13.3%), and one of these patients (case 9) was treated by corrective osteotomy, and the other (case 3) was treated by ipsilateral fibular transposition. Varus deformities seemed to be resulted from allograft resorption similar to allograft fracture. Two patients (13.3%) had limb leg discrepancies, which is treated by gradual lengthening, vascularized fibular bone graft and secure internal fixation after lengthening. In the follow-up radiograph, we observed resorption of allograft which was later remodeled by transposed fibula or vascularized fibula bone graft (case 3, 4, 10). The mean event-free survival was 60.6 months (range, 6–144 months). The 2-, 5-, and 10-year event-free survival rates were 61.1%, 55.0% and 13.7% respectively (Fig. 2).

Allograft was removed three of fifteen patients (20%). The causes

| No | Events | Overcome of events | Fibular use | Cause of allograft removal |
|----|--------|--------------------|-------------|---------------------------|
| 1  | Fracture at 69 months | Plating & bone graft | None | Local recurrence |
|    | Limb leg discrepancy at 81 months | Internal bone transport | None | |
| 2  | Infection at 101 months | Surgical debridement | None | Intact |
| 3  | Varus deformity at 21 months | Ipsilateral fibular transposition | Used | Intact |
| 4  | Limb leg discrepancy at 37 months | Lengthening of allograft & VFBG | Used | Intact |
| 5  | Nonunion at 6 months | Plating & bone graft | None | Intact |
| 6  | Infection at 98 months | Allograft removal | None | Infection |
| 7  | Nonunion at 9 months | Iliac bone graft | Used | Infection |
|    | Infection at 29 months | Allograft removal & VFBG | None | Intact |
| 8  | Varus deformity at 21 months | Corrective osteotomy & bone graft | None | Intact |
|    | Fracture at 36 months | Long leg cast | None | Intact |
| 9  | None | Not applicable | None | Intact |
| 10 | None | Not applicable | Used | Intact |
| 11 | None | Not applicable | None | Intact |
| 12 | None | Not applicable | None | Intact |
| 13 | None | Not applicable | None | Intact |
| 14 | None | Not applicable | None | Intact |
| 15 | None | Not applicable | None | Intact |

VFBG, vascularized fibular bone graft.
of removal were infection in two patients (case 6, 7) and local recurrence in one patient (case 1). Infection was effectively controlled by vascularized fibular bone graft (VFBG) in one patient (case 7). A patient with local recurrence was treated by insertion of tracers after allograft removal.

The mean allograft survival period was 80.2 months and the 2-, 5-, and 10-year allograft survival rates were 88.9%, 83.0%, and 60.5% respectively (Fig. 3). The mean MSTS scores were 73.5% (range, 46.6–90.0%) at the final point of the follow-up period.

Discussion

Allograft transplantation after malignant bone tumor and aggressive benign bone tumor have been reported to have a high rate of complications.\(^2\) Especially during the first 3 years the allograft resulted in fracture (19%), nonunion (17%) and infection (11%) before achieving stability with their grafts.\(^2\) Therefore most complications of allograft transplantation occurred within the first 3–5 years postoperatively.\(^2,3\) The events occurred at a mean of 53.1 months in our series.

The overall complication rate was high (60%) in our study. Similar studies reported the complication rates between 39% and 70%.\(^2,4,9,17\) Even though the complications occurred in 60% of the patients, only 20% of the patients with complication experienced allograft removal. These results corroborate even if most allograft transplantation experience such events, the removal of allograft can usually be avoided, case by case. However, other authors reported opposite results.\(^4,20\)

In four cases in our series, fibula bone was utilized by various methods such as fibula bone transposition and VFBG. Fibula transposition was performed in cases where proximal tibia had immature skeletal ages (case 3, 10). After mean follow up period of 137.5 months (165±110 months), allograft resorption and hypertrophy of fibula were observed. In the late 1980s, Capanna et al. introduced the concept of hybrid reconstruction by combining allograft shell with free vascularized fibula.\(^21\) Many authors reported that combined graft (VFBG + allograft) provided good results in reconstruction of proximal tibia.\(^22,23\) Fibular transposition is a simpler surgical method compared to VFBG, so fibular transposition can be option of biologic augmentation in proximal tibia reconstruction as the reason of anatomic neighboring districts.

VFBG was performed to reconstruct a segmental defect after gradual lengthening of allograft due to limb leg discrepancy (case 4) and to reconstruct a defect after removal of allograft due to infection (case 7). VFBG is the ideal material for reconstruction especially in the childhood.\(^22,23\) In a case of allograft removal, VFBG reconstruction was performed for infection control, VFBG was favorable when
compared with infection rates reported in allograft use (16~30%).29,30,37

In our series, 3 patients (20%) experienced infections. Infection is only the reason for allograft removal except for local recurrence. Allograft was removed in two cases and surgical debridement and antibiotics treatment was done in the other case. Graft failure rates after infection is over 80% and approximately one third of patients who have infected allograft eventually will need an amputation.20,27,29

Infections are difficult to avoid in these operations for numerous reasons: multiple surgeries, resection of large amounts of tissue, skin sloughing, adjuvant treatment, and poor blood supply to the allograft.25-28

Allograft fractures occurred in 13.3% of patients. In our series, there was no case of allograft removal after fracture. Many studies reported increased risk factors of allograft fracture, functional outcome after allograft fracture, strategies to reduce fracture rate, biomechanical behavior after allograft transplantation.3,11,12,14,18,20,28 In spite of these efforts, allograft fracture is still a common problem.

Nonunion occurred in 13.3%. In all cases, we achieved union after bone graft alone, or plating and bone graft. There was no case of allograft removal after nonunion. One study reported 30% of nonunions resulting in allograft failure, requiring replacement of the allograft or amputation of the limb.30 And Hornicek et al. reported three or more surgical attempts to correct the nonunion.30 Many studies reported increased risk factors of nonunion and reduced factors about surgical technique.25,29,30 As with fracture, nonunion was related to problems with incorporation of the dead allograft bone into the living host bone.6 If the living host bone has poor osteoinductive capacity, correcting a nonunion is expected to be difficult.6

Varus deformities (13.3%) occurred in proximal tibia. These deformities were corrected by corrective osteotomy (case 9) and ipsilateral fibula transposition (case 3). In the latter case, corrective osteotomy was performed at the proximal junction site due to progressive varus deformity. It may be the reason for allograft resorption and nonunion. In the follow-up radiograph, we observed varus deformities due to the result of allograft resorption similar to allograft fracture.

Limb leg discrepancies (13.3%) occurred in immature skeletal age. One case of LLD (case 1) was treated by internal bone transport and secure internal fixation. Another case of LLD (case 4) had internal bone transport of allograft and segmental defect was reconstructed by VFBG. Other two cases (case 3, 10) was augmented by ipsilateral fibular transposition in immature skeletal age before LLD was occurred. On last follow-up, the functional scores were acceptable (76%, 93%) and hypertrophied fibula seemed to have increasing bony mass up to a remodelling level, which can be considered as the outcome of its reactive hypertrophy.13,31 Compared to other reconstructive options, the use of allograft and VFBG showed superior outcome especially in skeletal immaturity as in LLD.22,23

Although rate of complication occurrence in allograft transplantation is high, published results for allografts show success rates of 66% to 84%.2,3,11,18,19,20 In our series, we also found high functional scores of 73.6% using MSTS scoring system. The lowest score was recorded in VFBG reconstruction after allograft infection (case 7, 46.6%). The highest score was recorded in a case that initially had ipsilateral fibula transposition with intercalary allograft reconstruction (case 10, 93%).

Until now VFBG is the most attractive option to prevent and overcome complications after allograft transplantation. Many authors described the advantages of combined grafts (vascularized fibular bone graft + massive bone allograft) in reconstruction following segmental skeletal resection for bone sarcoma.22,23,34 The use of the free vascularized fibular graft as a salvage method for complications of allograft reconstruction of the long bones has been reported.22,23 The rationale for a combined graft is to combine the advantages provided by the mechanical endurance of a massive allograft to the biological properties of the vascularized fibula graft. The allograft provides adequate bone stock and early stability, while the VFBC facilitates the host-allograft union and can hypertrophy.31,34

However VFBG is technically difficult and takes prolonged operative time. Moreover, long–learning curve is needed. Recently the repair of large defects by using prosthesis or hydroxyapatite bone substitutes combined with mesenchymal stem cells have become increasingly popular; moreover, allograft or autograft bones are also an attractive alternative to restore large segmental defects when combined with osteogenic proteins (like OP-1 or BMPs).11,30 Also there is hypothesis that the use of autologous bone marrow mononuclear cell has a role in the re–building of large segmental defects.11 Also, Lucarelli et al. reported that stromal stem cells and platelet–rich plasma could be a key role in bone repair.30

This study has the limitations of retrospective chart reviews without a control group, and standardization of surgical techniques. Other limitations include small sample size, variety among patients in diagnoses and location of tumor. Some patients in this study had a relatively short follow–up period.

Allograft reconstruction after bone tumor resection had a high rate of adverse events (60.0%) and allograft was removed in 20.0% during the follow–up period. Until now to overcome allograft related complications, the combination of an allograft and vascularized
fibular graft is highly recommended. In the near future, advance in tissue engineering technique and application of the stem cell and PRP to the allograft are expected to reduce the complication of allograft such as resorption and nonunion.

References

1. Donati D, Colangeli M, Colangeli S, Di Bella C, Mercuri M. Allograft-prosthetic composite in the proximal tibia after bone tumor resection, Clin Orthop Relat Res. 2008;466:459-65.

2. Mankin HJ, Gebhardt MC, Jennings LC, Springfield DS, Tomford WW. Long-term results of allograft replacement in the management of bone tumors. Clin Orthop Relat Res. 1996;86-97.

3. Hornicek FJ Jr, Mnaymneh W, Lackman RD, Exner GU, Malinin TI. Limb salvage with osteoarticular allografts after resection of proximal tibia bone tumors. Clin Orthop Relat Res. 1998;352:179-86.

4. Ogilvie CM, Crawford EA, Hosalkar HS, King JJ, Lackman RD. Long-term results for limb salvage with osteoarticular allograft reconstruction. Clin Orthop Relat Res. 2009;467:2685-90.

5. Prarrish F. Allograft replacement of all or part of the end of a long bone following excision of a tumor. J Bone Joint Surg Am. 1973;55:1-22.

6. Ottolenghi CE. Massive osteo and osteo-articular bone grafts. Technique and results of 62 cases. Clin Orthop Relat Res. 1972;87:156-64.

7. Muscolo DL, Ayerza MA, Aponte-Tinao LA. Long-term results of allograft replacement after total calanectomy. A report of two cases. J Bone Joint Surg Am. 2000;82:109-12.

8. Getty PJ, Peabody TD. Complications and functional outcomes of reconstruction with an osteoarticular allograft after intra-articular resection of the proximal aspect of the humerus. J Bone Joint Surg Am. 1999;81:1138-46.

9. Dick HM, Malinin TI, Mnaymneh WA. Massive allograft implantation following radical resection of high-grade tumors requiring adjuvant chemotherapy treatment. Clin Orthop Relat Res. 1985;88-95.

10. Ward WG, Heise E, Boles C, et al. Human leukocyte antigen sensitization after structural cortical allograft implantations. Clin Orthop Relat Res. 2005;31-5.

11. Giannini S, Vannini F, Lisiogoli G, Facchini A. Histological and immunohistochemical analysis of an allogenic bone graft engineered with autologous bone marrow mononuclear cells in the treatment of a large segmental defect of the ulna. A case report. Chir Organi Mov. 2008;91:171-5.

12. Myerson MS, Neufeld SK, Uribe J. Fresh-frozen structural allografts in the foot and ankle. J Bone Joint Surg Am. 2005;87:113-20.

13. Eward WC, Kontogeorgakos V, Levin LS, Brigman BE. Free vascularized fibular graft reconstruction of large skeletal defects after tumor resection. Clin Orthop Relat Res. 2010;468:590-8.

14. Heitmann C, Erdmann D, Levin LS. Treatment of segmental defects of the humerus with an osteoseptocutaneous fibular transplant. J Bone Joint Surg Am. 2002;84A:2216-23.

15. Enneking WF, Spanier SS, Goodman MA. Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am. 1980;62:1027-30.

16. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241-6.

17. Brigman BE, Hornicek FJ, Gebhardt MC, Mankin HJ. Allografts about the knee in young patients with high-grade sarcoma. Clin Orthop Relat Res. 2004;421:232-9.

18. Fox EJ, Hau MA, Gebhardt MC, Hornicek FJ, Tomford WW, Mankin HJ. Long-term followup of proximal femoral allografts. Clin Orthop Relat Res. 2002;397:106-13.

19. Muscolo DL, Ayerza MA, Aponte-Tinao LA. Survivorship and radiographic analysis of knee osteoarticular allografts. Clin Orthop Relat Res. 2000;373:73-9.

20. Ortiz-Cruz E, Gebhardt MC, Jennings LC, Springfield DS, Mankin HJ. The results of transplantation of intercalary allografts after resection of tumors. A long-term follow-up study. J Bone Joint Surg Am. 1997;79:97-106.

21. Capanna R, Bufalini C, Campanacci M. A new technique for reconstruction of large metadiaphyseal bone defects. A combined graft(allograft shell plus vascularized fibula). Orthop Traumatol. 1993;2:159-77.

22. Innocenti M, Abed Y, Beltrami G, Delcroix L, Manfrini M, Capanna R. Biological reconstruction after resection of bone tumors of the proximal tibia using allograft shell and intramedullary free vascularized fibular graft: long-term results. Microsurgery. 2009;29:361-72.

23. Bae D, Waters P, Gebhardt M. Results of free vascularized fib-
ula grafting for allograft nonunion after limb salvage surgery for malignant bone tumors. J Pediatr Orthop. 2006;26:809-14.
24. Sorger JI, Hornicek F, Zavatta M, et al. Allograft fractures revisited. Clin Orthop Relat Res. 2001;382:66-74.
25. Enneking WF, Campanacci DA. Retrieved human allografts: a clinicopathological study. J Bone Joint Surg Am. 2001;83A:971-86.
26. Lord CF, Gebhardt MC, Tomford WW, Mankin HJ. Infection in bone allografts: incidence, nature, and treatment. J Bone Joint Surg Am. 1988;70:369-76.
27. Mnaymneh W, Malinin TI, Makley JT, Dick HM. Massive osteoarticular allografts in the reconstruction of extremities following resection of tumors not requiring chemotherapy and radiation. Clin Orthop Relat Res. 1985;197:76-87.
28. Berrey BH Jr, Lord CF, Gebhardt MC, Mankin HJ. Fractures of allografts. Frequency, treatment, and end-results. J Bone Joint Surg Am. 1990;72:825-33.
29. Vander Griend RA. The effect of internal fixation on the healing of large allografts. J Bone Joint Surg Am. 1994;76:657-63.
30. Hornicek FJ, Gebhardt MC, Tomford WW, et al. Factors affecting nonunion of the allograft-host junction. Clin Orthop Relat Res. 2001;382:87-98.
31. Ceruso M, Taddei F, Bigazzi P, Manfrini M. Vascularised fibula graft inlaid in a massive bone allograft: considerations on the bio-mechanical behaviour of the combined graft in segmental bone reconstructions after sarcoma resection. Injury. 2008;39 Suppl 3:S68-74.
32. Friedrich JB, Moran SL, Bishop AT, Wood CM, Shin AY. Free vascularized fibular graft salvage of complications of long-bone allograft after tumor reconstruction. J Bone Joint Surg Am. 2008;90:93-100.
33. Chang DW, Weber KL. Use of a vascularized fibula bone flap and intercalary allograft for diaphyseal reconstruction after resection of primary extremity bone sarcomas. Plast Reconstr Surg. 2005;116:1918-25.
34. Chang DW, Weber KL. Segmental femur reconstruction using an intercalary allograft with an intramedullary vascularized fibula bone flap. J Reconstr Microsurg. 2004;20:195-9.
35. Moran SL, Shin AY, Bishop AT. The use of massive bone allograft with intramedullary free fibular flap for limb salvage in a paediatric and adolescent population. Plast Reconstr Surg. 2006;118:413-9.
36. Lucarelli E, Fini M, Beccheroni A, et al. Stromal stem cells and platelet-rich plasma improve bone allograft integration. Clin Orthop Relat Res. 2005;435:62-8.
골종양 절제 후 동종골을 이용한 재건술의 합병증 및 해결방법

조 울* 최 영* 권영호* 정소학* 김재도*
국군수도병원 정형외과, *고신대학교 복음병원 정형외과

목적: 골종양을 절제한 후 동종골을 이용한 재건술 후 발생한 합병증을 평가하고 그 합병증에 대한 문헌고찰을 하고자 한다.
대상 및 방법: 골종양 절제 후 동종골을 이용한 재건술을 시행한 15예에 대하여 임상적 및 방사선학적 자료를 통해 후향적으로 연구를 시행하였다.
결과: 남자가 8예, 여자가 7예이었으며 평균 나이는 27.1세(1-56세), 평균 추시 기간은 91.5개월(33-146개월)였다. 21예(80.0%)에서 평균 8.35개월(4-12 개월)에 방사선학적 골유합 소견을 보였다. Musculoskeletal Tumor Society 점수 평균은 73.5%(46.6-93.0%)였다. 동종골 이식과 관련된 술 후 합병증을 모두 기록하였다. 추시 기간 동안 9예(36.0%)에서 한 가지의 합병증이 발생하였고 3예(20.0%)에서 두 가지 이상의 합병증이 발생하였다. 합병증으로는 감염 3예, 골절 2예, 불유합 2예, 하지 부동 2예, 내반 변형이 2예였다. 합병증이 발생하지 않은 평균 기간은 60.8개월(6-144개월)이었다. 동종골의 평균 생존기간은 80.2개월이었고 5년 생존율은 83.0%였다.
결론: 동종골의 합병증을 줄이기 위하여 동종골을 이용한 재건술시 자가비골을 추가하는 것이 추천된다. 더 나아가 조직 공학 기술과 줄기세포 및 혈소판 부유 혈장의 적용이 동종골의 재흡수나 불유합 등의 합병증을 줄일 수 있을 것으로 생각된다.

색인단어: 골종양, 동종골 재건술, 합병증

접수일 2011년 5월 21일 심사수정일 2011년 11월 26일 게재확정일 2011년 11월 30일
교신저자 김재도,
부산시 서구 암남동 34번지, 고신대학교 복음병원 정형외과
TEL: 051-990-6367, FAX: 051-243-0181, E-mail: jdkim@ns.kosinmed.or.kr